Antibiotic therapy in pregnancy

Česká verzia

Authors: M. Štefan ¹; J. Vojtěch ²
Authors place of work: Klinika infekčních nemocí 1. LF UK a ÚVN, Praha, přednosta prof. M. Holub, Ph. D. ¹; Ústav pro péči o matku a dítě, Praha, ředitel doc. MUDr. J. Feyereisl, CSc. ²
Published in the journal: Ceska Gynekol 2018; 83(1): 70-80

Summary

Objective:
This article reviews up-to-date data on antibiotic therapy in pregnancy.

Design:
Review article.

Setting:
Department of Infectious Diseases, Military University Hospital Prague; Institute for the Care of Mother and Child, Prague.

Material and methods:
Relevant literary sources have been considered, including articles in English indexed in Pubmed, monographies in English and articles in Czech.

Conclusions:
Antibiotic therapy in pregnancy must be rational. Antibiotics with favorable risk-benefit ratio should be used whenever possible. To achieve this, physicians must be well versed in the topic of toxicity and teratogenicity of the most commonly used antibiotics. Several pharmacokinetic parameters are altered in pregnant women. Thus, dosage of some antibiotics should be adjusted (usually increased) accordingly. Antibiotic therapy in perinatal period and in early childhood might increase the risk of developing atopy and obesity.

Keywords:
antibiotics, pregnancy, infection, teratogenicity, pharmacokinetics

Zdroje

1. Adámková, V., Balík, M., Bláha, J., et al. Mezioborový doporučený postup – diagnostika a léčba sepse v souvislosti s těhotenstvím. Čes Gynek, 2016, 81, 2, p. 134–139.

2. Amsden, GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther, 1996, 1, p. 56–72.

3. Andersen, JT., Petersen, M., Jimenez-Solem, E., et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One, 2013, 8, 1, e53327.

4. Bartlett, JG. (ed.) The John Hopkins ABX Guide (online). [cit. 2017-07-03]. Dostupný z www: http:// www.hopkinsguides.com/hopkins/index/Johns_Hopkins_ABX_Guide/All_Topics/A.

5. Bennett, JE. (ed.) Mandell, Douglas and Benett´s principles and practice of infectious diseases. Saunders, 2014, 3904 s.

6. Berkovitch, M., Diav-Citrin, O., Greenberg, R., et al. First-trimestr exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol, 2004, 58, 3, p. 298–302.

7. Bookstaver, PB., Bland, CM., Griffin, B., et al. A review of antibiotic use in pregnancy. Pharmacotherapy, 2015, 35, 11, p. 1052–1062.

8. Bothamley, G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf, 2001, 24, 7, p. 553–565.

9. Brodt, HR. Antibiotika – Therapie. Klinik und Praxis der antiinfektiösen Behandlung. Stuttgart: Schattauer, 2013, 1086 s.

10. Brouillard, JE., Terriff, CM., Tofan, A., et al. Antibiotic selection and resistence issues with fluoroquinolones and doxycykline againts bioterrorism agents. Pharmacotherapy, 2006, 26, 1, p. 3–14.

11. Burtin, P., Taddio, A., Ariburnu, O., et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol, 1995, 172, 2 Pt 1, p. 525–529.

12. Cox, LM., Blaser, MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol, 2015, 11, 3, p. 182–190.

13. Cross, R., Ling, C., Day, NP. Revisiting doxycycline in pregnancy and early childhood-time to rebuild its reputation? Expert Opin Drug Saf, 2016, 15, 3, p. 367–382.

14. Czeizel, AE., Rockenbauer, M., Sørensen, HT., et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol, 2001, 15, 6, p. 637–646.

15. Diav-Citrin, O., Schechtman, S., Gotteiner, T., et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology, 2001, 63, 5, p. 186–192.

16. Džupová, O. Antibiotická léčba v graviditě. Farmakoterapie, 2005, 1, 5, s. 525–527.

17. Ehsanipoor, RM., Chung, JH., Clock, CA., et al. A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes. Am J Obstet Gynecol, 2008, 198, p. e54–e56.

18. Eppes, CS., Clark, SL. ESBL infections during pregnancy: a growing threat. Am J Obstet Gynecol, 2015, 213, 5, p. 650–652.

19. Food and Drug Administration. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed Reg, 1979, 44, p. 37434–37467.

20. Food and Drug Administration. Content and format of labeling for human prescription drug and biologic products; requirements for pregnancy and lactation labeling. Final rule. Fed Reg, 2014, 79, 233, p. 72063–72103.

21. Ford, N., Shubber, Z., Jao, J., et al. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr, 2014, 66, 5, p. 512–521.

22. French, G. Safety and tolerability of linezolid. J Antimicrob Chemother, 2003, 51, Suppl. 2, ii45–53.

23. Goldberg, O., Moretti, M., Levy, A., et al. Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis. J Obstet Gynaecol Can, 2015, 2, p. 150–156.

24. Greenwood, D. Antimicrobial drugs. Chronicle of a twentieth century medical triumph. New York: Oxford University Press, 2008, 429 s.

25. Hernandez-Diaz, S., Werler, MM., Walker, AM., et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med, 2000, 343, 22, p. 1608–1614.

26. Kacerovský, M., Kokrdová, Z., Koucký, M., et al. Spontánní předčasný porod. Doporučený postup. Čes Gynek, 2017, 82, 2, p. 160–165.

27. Kazy, Z., Puho, E., Czeizel, AE. Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol, 2005, 20, 2, p. 181–182.

28. Kladenský, J., Toršová, V., Chmelařová, E. Přínos nifuratelu pro léčbu akutních nekomplikovaných uroinfekcí. Urolog pro Praxi, 2006, 3, s. 108–110.

29. Koumans, EH., Markowitz, LE., Hogan, V., CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis, 2002, 35, Suppl. 2, s. 152–172.

30. Lamont, HF., Blogg, HJ., Lamont, RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf, 2014, 13, 12, p. 1569–1581.

31. Linseman, DA., Hampton, LA., Branstetter, DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol, 1995, 28, 1, p. 59–64.

32. Matok, I., Gorodischer, R., Koren, G., et al. Exposure to folic acid antagonists during the first trimestr of pregnancy and the risk of major malformations. Br J Clin Pharmacol, 2009, 68, 6, p. 956–962.

33. Měchurová, A., Vlk, R., Unzeitig, V. Diagnostika a léčba streptokoků skupiny B v těhotenství a za porodu – doporučený postup. Čes Gynek, 2013, 78, s. 11–S14.

34. Muanda, FT., Sheehy, O., Bérard, A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ, 2017, 189, 17, E625–633.

35. Mueller, NT., Bakacs, E., Combellick, J., et al. The infant microbiome development: mom matters. Trends Mol Med, 2015, 21, 2, p. 109–117.

36. Nahum, GG., Uhl, K., Kennedy, DL. Antibiotic use in pregnancy and lactation: what is and what is not known about teratogenic and toxic risks. Obstet Gynecol, 2006, 107, 5, p. 1120–1138.

37. Robinson, GC., Cambon, KG. Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy. N Engl J Med, 1964, 271, p. 949–951.

38. Rovamycine 1.5 M.I.U. Souhrn údajů o přípravku (online). [cit. 2017-07-03]. Dostupný z www: www.sukl.cz

39. Roxithromycin-ratiopharm 150 mg. Souhrn údajů o přípravku (online). [cit. 2017-07-03]. Dostupný z www: www.sukl.cz

40. Schweizer, ML., Furuno, JP., Harris, AD., et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis, 2011, 11, p. 279.

41. Sodhi, M., Axtell, SS., Callahan, J. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother, 2004, 54, 6, p. 1155–1157.

42. Štefan, M, Holub, M. Ambulantní parenterální antibiotická terapie. Čas Lék Čes, 2016, 155, s. 21–24.

43. Tita, ATN., Andrews, WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol, 2010, 37, 2, p. 339–354.

44. Toršová, V., Chmelařová, E. Antibiotika v těhotenství. Interní Med, 2001, 12, s. 550–552.

45. van de Mheen, L., Smits, SM., Terpstra, WE., et al. Haemolytic anemia after nitrofurantoin treatment in a pregnant woman with G6PD deficiency. BMJ Case Rep, 2014, p. 1–4. Published online.

46. Wegienka, G., Zoratti, E., Johnson, CC. The role of the early-life environment in the development of allergic disease. Immunol Allergy Clin North Am, 2015, 35, 1, p. 1–17.

47. Weintraub, AS., Ferrara, L., Deluca, L., et al. Antenatal antibiotic exposure in preterm infants with necrotizing enterocolitis. J Perinatol, 2012, 32, 9, p. 705–709.

48. Yefet, E., Salim, R., Chazan, B., et al. The safety of quinolones in pregnancy. Obstet Gynecol Surv, 2014, 69, 11, p. 681–694.